These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38702967)

  • 21. lncRNA AFAP1-AS1 promotes triple negative breast cancer cell proliferation and invasion via targeting miR-145 to regulate MTH1 expression.
    Zhang X; Zhou Y; Mao F; Lin Y; Shen S; Sun Q
    Sci Rep; 2020 May; 10(1):7662. PubMed ID: 32376943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Knockdown of long noncoding RNA TP73-AS1 suppresses the malignant progression of breast cancer cells in vitro through targeting miRNA-125a-3p/metadherin axis.
    Liu Y; Wei G; Ma Q; Han Y
    Thorac Cancer; 2020 Feb; 11(2):394-407. PubMed ID: 31901156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a.
    Lin C; Zheng M; Yang Y; Chen Y; Zhang X; Zhu L; Zhang H
    Bioengineered; 2022 Apr; 13(4):9829-9838. PubMed ID: 35412951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis.
    Hu J; Huang H; Xi Z; Ma S; Ming J; Dong F; Guo H; Zhang H; Zhao E; Yao G; Yang L; Zhang F; Zheng W; Chen H; Huang T; Li L
    Cell Death Dis; 2022 Sep; 13(9):800. PubMed ID: 36123344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long Noncoding RNA FBXL19-AS1-Mediated Ulcerative Colitis-Associated Intestinal Epithelial Barrier Defect.
    Zhao X; Cui DJ; Yang LC; Yuan WQ; Yan F
    Tissue Eng Regen Med; 2022 Oct; 19(5):1077-1088. PubMed ID: 36048401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.
    Zhu S; Sun J; Liu X; Shao H; Feng C; Wang Z; Zheng X; Wei S
    Mol Cell Biol; 2022 Jun; 42(6):e0018821. PubMed ID: 35499320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis.
    Ding Y; Huang Y; Zhang F; Gong L; Liang C; Ding K; He X; Ding X; Chen Y
    J Transl Med; 2023 Nov; 21(1):854. PubMed ID: 38008726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA PSMA3-AS1 promotes cell proliferation, migration, and invasion in ovarian cancer by activating the PI3K/Akt pathway via the miR-378a-3p/GALNT3 axis.
    Xu Z; Jin H; Duan X; Liu H; Zhao X; Fan S; Wang Y; Yao T
    Environ Toxicol; 2021 Dec; 36(12):2562-2577. PubMed ID: 34520102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-378a-3p acts as a tumor suppressor in gastric cancer
    Xu X; Li Y; Liu G; Li K; Chen P; Gao Y; Liang W; Xi H; Wang X; Wei B; Li H; Chen L
    Cancer Biol Med; 2022 Oct; 19(12):1662-82. PubMed ID: 36245214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The knockdown of LncRNA AFAP1-AS1 suppressed cell proliferation, migration, and invasion, and promoted apoptosis by regulating miR-545-3p/hepatoma-derived growth factor axis in lung cancer.
    Sun J; Min H; Yu L; Yu G; Shi Y; Sun J
    Anticancer Drugs; 2021 Jan; 32(1):11-21. PubMed ID: 33290312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis.
    Li H; Wang D; Yi B; Cai H; Wang Y; Lou X; Xi Z; Li Z
    Int J Biol Sci; 2021; 17(11):2912-2930. PubMed ID: 34345216
    [No Abstract]   [Full Text] [Related]  

  • 33. FBXL19-AS1 promotes cell proliferation and inhibits cell apoptosis via miR-876-5p/FOXM1 axis in breast cancer.
    Dong G; Pan T; Zhou D; Li C; Liu J; Zhang J
    Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1106-1113. PubMed ID: 31696201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
    Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
    J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic lncRNA ZNF561-AS1 is essential for colorectal cancer proliferation and survival through regulation of miR-26a-3p/miR-128-5p-SRSF6 axis.
    Si Z; Yu L; Jing H; Wu L; Wang X
    J Exp Clin Cancer Res; 2021 Feb; 40(1):78. PubMed ID: 33622363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA ZNF667-AS1 Targets miR-523-3p/KIF5C Axis to Hinder Colon Cancer Progression.
    Tong D; Fan L
    Mol Biotechnol; 2024 Jun; 66(6):1464-1476. PubMed ID: 37322260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
    Han C; Fu Y; Zeng N; Yin J; Li Q
    Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis.
    Li D; Zhong S; Zhu Z; Jiang X; Zhang J; Gu J; Chen F
    Pathobiology; 2020; 87(6):345-355. PubMed ID: 33238264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
    Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
    Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.
    Zhou Y; Li K; Zou X; Hua Z; Wang H; Bian W; Wang H; Chen F; Dai T
    Bioengineered; 2021 Dec; 12(2):10862-10877. PubMed ID: 34666613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.